Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
In the latest edition of our regular podcast that looks at upcoming catalysts, it was the turn of Vantage’s deputy editor Amy Brown to join me in the podcast studio.
This quarter, it’s like a rollcall of all the key indications that have been in the spotlight in recent months and years. Alzheimer’s, obesity, RSV…there’s something coming up for all of them. One of the biggest readouts we ponder is Novo’s attempt to claim a cardiovascular benefit with its obesity juggernaut Wegovy. Of course, we cover some of the latest in oncology too, including the thresholds that Immunogen needs to meet with its confirmatory Mirasol study.
It’s all wrapped up in a quick chat between me and Amy, so grab your headphones and listen in. You’ll also find all the stories we reference conveniently below as well. Enjoy!
Our catalyst stories
Major readouts on the horizon for small developers | Evaluate
Biotech heads towards big catalysts | Evaluate